Skip to content

February 14, 2026

Rakesh Jhunjhunwala

Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Articles
Portfolios
- Rakesh Jhunjhunwala Latest Portfolio
- Dolly Khanna Latest Portfolio, Holdings, Wiki, News | December 2023
Research Reports
Stocks Talk
Top Stock Picks 2024 | Live Portfolio Tracker

Light/Dark Button

Search for:

Home
investments
Biosecure Act Passage Triggers Rally in Indian Pharma CDMO Stocks; Macquarie Reiterates ‘Outperform’
Screenshot 2025-10-10 at 17-08-32 DIVISLAB ₹6 489.00 (▲5.82_) Divi’s Laboratories Ltd Google Finance

Screenshot 2025-10-10 at 17-08-32 DIVISLAB ₹6 489.00 (▲5.82_) Divi’s Laboratories Ltd Google Finance

Post navigation

Previous Previous post:

Biosecure Act Passage Triggers Rally in Indian Pharma CDMO Stocks; Macquarie Reiterates ‘Outperform’

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Current ye@r *

Leave this field empty

Subscribe to Telegram Channel

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Join 582 other subscribers

Recent Comments

Kamal Garg on LG Electronics is India’s leading home appliances brand & has retained pole position across categories. Buy for target price of ₹1630 (18.9% upside): JMFICS
Kamal Garg on Suzlon Energy Risk-reward is favorable at current levels. Buy for target price of ₹74 (54% upside): Motilal Oswal
Mukul on LG Electronics is a high-quality consumer franchise with strong cash generation, leadership positioning and long-term growth visibility. Buy for Bull Case Fair Value of ₹1780 (16% upside): HDFC Sec
gokulram arunasalam on Vijay Kedia’s Tweet on Gold vs. Equities Sparks a Debate on the Purpose of Wealth
gokulram arunasalam on Top 15 companies from the NSE 500 basket that provide higher dividend yields by IDBI Capital

Search for:

Recent Posts

Dollar Industries has strong brand recall & favourable macro tailwinds. Buy for target price of ₹470 (52% upside): SMIFS
Kalyan Jewellers has established itself as a leading brand in the industry. Buy for target price of ₹600 (58% upside): Motilal Oswal
GR Infraprojects has a Strong & Well-diversified Order Book Ensuring Revenue Visibility. Buy for target price of ₹1540 (55% upside): Axis Securities
Man Industries has stellar growth potential. Buy for target price of ₹694 (80.7% upside): SBI Securities
Crompton Greaves Consumer Electricals 3QFY26 earnings were above estimates. Buy for target price of ₹350 (43% upside): Motilal Oswal

You may have missed

Dollar share price target

investments

Dollar Industries has strong brand recall & favourable macro tailwinds. Buy for target price of ₹470 (52% upside): SMIFS

February 13, 2026 0

kalyanjkil share price target

investments

Kalyan Jewellers has established itself as a leading brand in the industry. Buy for target price of ₹600 (58% upside): Motilal Oswal

February 12, 2026 0

GR Infraprojects share price target

investments

GR Infraprojects has a Strong & Well-diversified Order Book Ensuring Revenue Visibility. Buy for target price of ₹1540 (55% upside): Axis Securities

February 11, 2026 0

man industries share price target

investments

Man Industries has stellar growth potential. Buy for target price of ₹694 (80.7% upside): SBI Securities

February 10, 2026 0

Crompton Greaves Consumer Electricals share price target

investments

Crompton Greaves Consumer Electricals 3QFY26 earnings were above estimates. Buy for target price of ₹350 (43% upside): Motilal Oswal

February 9, 2026 0

jubilant pharmova share price target

investments

Jubilant Pharmova has an aspirational target for FY30 of doubling of overall revenues. Buy for target price of ₹1310 (41% upside): ICICI Direct

February 8, 2026 0

Copyright © All rights reserved. | ChromeNews by AF themes.